Vanda Pharmaceuticals (VNDA) Common Equity (2009 - 2026)

Vanda Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $280.8 million for Q1 2026.

• In Q1 2026, Common Equity fell 45.1% year-over-year to $280.8 million; the TTM figure through Mar 2026 stood at $280.8 million (down 45.1% YoY), while the FY2025 annual figure was $327.2 million, down 39.25% from the prior year.
• Common Equity came in at $280.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $327.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $544.9 million in Q4 2023 to a low of $280.8 million in Q1 2026.
• A 5-year average of $497.4 million and a median of $527.2 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity climbed 7.38% in 2022 and slumped 45.1% in 2026, its largest moves.
• Vanda Pharmaceuticals' Common Equity stood at $527.2 million in 2022, then gained by 3.36% to $544.9 million in 2023, then slipped by 1.17% to $538.5 million in 2024, then plunged by 39.25% to $327.2 million in 2025, then slipped by 14.19% to $280.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $280.8 million, $327.2 million, and $466.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison